Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease Article

Industry Collaboration International Collaboration

cited authors

  • Socinski, Mark A.; Kaye, Frederic J.; Spigel, David R.; Kudrik, Fred J.; Ponce, Santiago; Ellis, Peter M.; Majem, Margarita; Lorigan, Paul; Gandhi, Leena; Gutierrez, Martin E.; Nepert, Dale; Corral, Jesus; Paz Ares, Luis

authors

Publication Date

  • January 1, 2017

webpage

published in

category

keywords

  • Clinical trial
  • Combination therapy
  • SCLC
  • Targeted drug delivery
  • Tolerability

start page

  • 68

end page

  • 76

volume

  • 18

issue

  • 1